Glioma Clinical Trial
Official title:
The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma and Its Correlation to EGFRvIII
The epidermal growth factor receptor variant Ⅲ(EGFR vⅢ) is commonly detected in high-grade
gliomas, which is also an important epitope in EGFR-targeted therapies and correlated to
poor prognosis. However, detection of this mutant usually needs resected tumor samples. For
biopsy samples, test results may not represent the EGFR vⅢ status of the whole tumor tissues
because of the heterogeneity of tumor. It is also not applicable for patients who are not
suitable for surgical procedure due to the tumor location or patients' general conditions.
Because of the importance of the epidermal growth factor receptor (EGFR) signal pathway in
oncogenesis, maintenance, and progression of high grade glioma, there has been an intense
effort to develop noninvasive molecular imaging approach for the selection and monitoring of
EGFR-targeted therapies.
Based on investigators' previous study, investigators plan to perform PET scanning on the
participants with high grade gliomas after the injection of the second generation of EGFR
tracer ,89Zr-ABT806, which can be specifically binded to EGFR vⅢ . After fusing the PET and
MRI images, investigators precisely obtain the tissue from the"hot-spot" on the PET image
through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status will be detected by
molecular methods to analyze the correlation with the 89Zr-ABT806 PET image qualitatively
and quantitatively. Investigators' final goal is to detect EGFR vⅢ by noninvasive molecular
imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted
therapies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
| Enrolling by invitation |
NCT04461002 -
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
|
||
| Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
| Completed |
NCT03242824 -
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
|
Phase 2 | |
| Recruiting |
NCT04186832 -
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
|
N/A | |
| Completed |
NCT00424554 -
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
|
Phase 2 | |
| Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
| Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
| Completed |
NCT02805179 -
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
|
Phase 2 | |
| Terminated |
NCT04556929 -
Enhanced Detection in Glioma Excision
|
N/A | |
| Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
| Recruiting |
NCT06043232 -
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
|
||
| Not yet recruiting |
NCT06043765 -
Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
|
N/A | |
| Not yet recruiting |
NCT05025969 -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
|
||
| Completed |
NCT02978261 -
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
|
Phase 1 | |
| Completed |
NCT01836536 -
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
|
N/A | |
| Terminated |
NCT01502605 -
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
|
Phase 1 | |
| Completed |
NCT01479686 -
iMRI Guided Resection in Cerebral Glioma Surgery
|
Phase 3 | |
| Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
| Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A |